AD Pipeline Watch: First Patient Enrolled in Phase 2 Study of Evommune’s IL-18 Blocker March 17, 2025
AD Pipeline Watch: Amgen, Kyowa Kirin’s Anti-OX40 Candidate Meets Endpoints in AD Trial March 10, 2025